INTERESTING EYE NEWS & CLINICAL PEARLS

  A retrospective cohort study analyzed electronic healthcare data from 70 US facilities (2005–2025) to evaluate how high-density lipoprotein cholesterol (HDL-C) levels impact the risk of age-related macular degeneration (AMD). Key Findings Higher Dry AMD Risk: High HDL-C levels were associated with a significantly increased risk of incident nonexudative (dry) AMD across all stages compared to low levels. Weaker Wet AMD Link: The association with exudative (wet) AMD was present but weaker and less consistent. Risk Breakdown (Hazard Ratios): Overall Dry AMD:Early Atrophic Stage: HR = 1.55 Intermediate Atrophic Stage: HR = 1.82 Advanced Atrophic Stage: HR = 1.85 Overall Wet AMD: HR = 1.37 Study Design & Methodology Researchers matched 186,532 subjects into high and low HDL-C groups based on demographics, medications, and comorbidities. The risk estimates remained directionally consistent and stable even after adjusting for these variables. The authors concluded that future st...

 Bausch + Lomb has introduced PreserVision AREDS3 , an over-the-counter oral supplement designed to reduce the risk of disease progression in patients with age-related macular degeneration (AMD). Key Features & Formulation Core Nutrients: Contains the complete, National Eye Institute-recommended AREDS2 formula to protect macular health by neutralizing free radicals (vitamins C and E, lutein, zeaxanthin, zinc, and copper). New B-Vitamin Complex: Adds thiamin, riboflavin, niacin, pantothenic acid, vitamin B6, biotin, folate, and vitamin B12 to promote healthy cellular eye function. Enhanced Absorption: Offers approximately twice the nutrient absorption of previous AREDS formulations. Scientific Backing The inclusion of B vitamins is supported by over two decades of research across more than 20 human studies (including the Women’s Antioxidant and Folic Acid Cardiovascular Study ), which tie specific B-vitamin supplementation to a reduced risk of AMD. Bausch + Lomb plans to con...

A retrospective cohort study published in Ophthalmology suggests that NSAIDs may reduce the risk of developing age-related macular degeneration (AMD) . Because inflammation plays a central role in both wet (exudative) and dry (non-exudative) AMD, researchers in Taiwan investigated whether the anti-inflammatory properties of these drugs offer a protective effect. Key Findings The study compared 634,794 patients prescribed NSAIDs against an equal number of non-users (both groups averaging roughly 60 years old) and found: Sustained Protection: NSAID users showed a reduced risk for AMD across all tracked time points, including at six months (HR: 0.31), one year (HR: 0.36), three years (HR: 0.42), and five years (HR: 0.48). Over the entire study duration, the overall hazard ratio was 0.58. Drug Types: The protective effect was observed both in patients prescribed aspirin (HR: 0.72) and those taking non-selective COX inhibitors other than aspirin (HR: 0.41). Subtypes & Comorbiditie...

A study from the ARVO 2026 meeting confirms that early intervention for geographic atrophy (GA) using pegcetacoplan (Syfovre) significantly improves long-term outcomes compared to delayed treatment. Key Study Findings Researchers analyzed 782 patients transitioning from the two-year OAKS/DERBY trials into the three-year GALE extension study. Superior Tissue Preservation: Patients who started treatment immediately (early group) preserved 3.87 mm² of retinal tissue over five years. Those who started two years late (delayed group) preserved only 1.93 mm² . Reduced Growth Rates: In nonsubfoveal GA, monthly injections reduced lesion growth by 33% compared to the sham group. Disease Delay: Continuous five-year therapy delayed the progression of nonsubfoveal GA by approximately 16.5 to 18.5 months . Safety Profile: The treatment remained well-tolerated over five years. Rare instances of retinal vasculitis occurred in fewer than 1 in 4,000 cases, consistent with earlier trial data. C...

A study presented at the ARVO 2026 meeting suggests that bupropion (Wellbutrin) may slow the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. Researchers believe the drug’s ability to reduce systemic inflammatory cytokines contributes to these protective ocular effects. Key Study Results Using the Chang Gung Research Database in Taiwan, researchers compared 1,574 adults with preexisting DR. Patients taking bupropion showed significantly better outcomes than non-users: Complication Reduction: Bupropion users had a 6.9% incidence of major DR complications (like retinal detachment or vitreous hemorrhage) compared to 12.8% in the control group. Fewer Interventions: There was a substantial drop in the need for retinal lasers, vitrectomies, or intravitreal injections. Broad Ocular Benefits: The data also indicated a lower risk of developing cataracts and glaucoma , as well as a reduced need for intraocular pressure-lowering medications. Conclusion While t...

  A retrospective cohort study presented at ARVO 2026 , which suggests that GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) may offer protective benefits for eye health in non-diabetic adults with a BMI of 27 or higher. Key Findings The study compared over 31,000 patients using these medications for weight loss against a matched group with no GLP-1 prescriptions. Over a four-year period, those on GLP-1 drugs showed a reduced risk for several major ocular conditions: Significant Reductions: The most robust protection was seen against Age-Related Macular Degeneration (AMD) , both dry and wet forms. Glaucoma Protection: Use was associated with a strong reduction in the risk of both primary open-angle and angle-closure glaucoma. Macular Health: There was a moderate decrease in the incidence of cystoid macular edema (CME). Surprising Results: Contrary to some previous studies, this data showed a slight reduction in the risk of NAION (non-arteritic isch...

 This study, presented at the 2026 ARVO conference , suggests a significant link between periodontal disease and various ocular conditions . Using anonymized medical records from over 25,000 patients, Texas researchers conducted a 10-year retrospective analysis comparing individuals with gum disease to a healthy control group. Key Research Findings After adjusting for variables like smoking and comorbidities, the study found that patients with periodontal disease face a higher risk for: Anterior Segment Issues: Conjunctivitis, blepharitis, and dry eye syndrome. Vision-Threatening Diseases: Open-angle glaucoma, cataracts, and retinal artery occlusion. Inflammatory Conditions: Iridocyclitis and chorioretinal inflammation. Clinical Implications The authors conclude that chronic oral inflammation may contribute to systemic issues that harm eye health. Consequently, they recommend that patients with a history of gum disease undergo more rigorous ophthalmic screening to catch these ...

  This study, presented at ARVO 2026, suggests that high-intensity statin therapy significantly lowers the risk of progression from intermediate to "wet" age-related macular degeneration (AMD) . Researchers believe statins may slow the buildup of drusen —lipid-rich deposits under the retina—similar to how they manage plaques in heart disease. Key Study Findings Over a 30-month follow-up of 124 patients, the researchers observed: Reduced Risk: Statin users had a 46% lower risk of overall AMD progression compared to non-users. Wet AMD Prevention: High-intensity statin use specifically reduced the risk of converting to neovascular (wet) AMD by 70% . Vision Preservation: High-intensity users were 59% less likely to suffer significant visual acuity loss and showed better preservation of contrast sensitivity. Drusen Impact: Treatment was associated with a slower increase in drusen volume, though it did not appear to impact progression toward geographic atrophy (dry AMD). Cli...

  Key Findings from ARVO 2026 Researchers tracked 247 patients with primary open-angle glaucoma (POAG) over five years and found that those with high myopia (≤ -6.00D) experienced faster vision loss and required stricter pressure control than those with mild or moderate myopia. Progression Rates: High myopes saw a mean deviation (MD) decline of -0.30dB/year , significantly faster than moderate (-0.18dB/year) or low myopes (-0.07dB/year). Target Pressure: To keep vision loss below a safe threshold, the study recommends maintaining an intraocular pressure (IOP) below 17.1mm Hg for high myopes. In contrast, targets near 19mm Hg were acceptable for other groups. Clinical Implications The study concludes that a "one-size-fits-all" approach to eye pressure is insufficient. Because high myopes face a higher risk of rapid deterioration at standard pressure levels, eye doctors must set more aggressive, personalized IOP goals to effectively preserve their vision.